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Anal Injectable and Implantable 
Bulking Agents for Faecal 
Incontinence
John Camilleri-Brennan
Abstract
Faecal incontinence (FI) is a common condition, the prevalence of which 
increases with age. It is associated with a negative impact on the quality of one’s 
life. The aetiology is multifactorial; hence, both the diagnosis and the treatment 
of faecal incontinence may be challenging. A variety of surgical treatments for 
faecal incontinence have emerged over the years. One of these is the use of anal 
bulking agents. Anal bulking agents have been available for over 25 years, with 
various studies being published. Initial results were disappointing, mainly due to 
lack of efficacy and reliability as well as concerns about safety. Great strides have 
been made recently with the introduction of the anal implants Gatekeeper (GK) 
and Sphinkeeper (SK). This chapter explores the evolution of anal injectables and 
implants, discusses operative techniques and provides a critical analysis of the 
results of the various studies to date.
Keywords: faecal incontinence, anal sphincter, anal implants, anal injectables, 
anal bulking agents, gatekeeper, Sphinkeeper
1. Introduction
Faecal incontinence (FI) may be defined as an impaired ability of the control 
of the release of flatus or faeces. It is a socially stigmatising condition that may 
have an adverse effect on one’s quality of life. From the financial point of view, the 
investigation and treatment of faecal incontinence may add to a significant cost to 
the health systems of most countries. In fact, the annual treatment cost of patients 
in the UK with urinary and faecal incontinence is of about £500 million.
Many factors may be involved in the pathophysiology of FI. A thorough clinical 
assessment of the patient is therefore mandatory. This starts with a full history, which 
may include a cognitive assessment if necessary. The characteristics of the faeces and 
the type and frequency of incontinence should be noted. Urge incontinence is sugges-
tive of poor external anal sphincter (EAS) function, whilst passive and post-defae-
catory incontinence indicates that internal anal sphincter (IAS) function is weak. 
Various questionnaires that enable the clinician to quantify the degree of incontinence 
and the impact on quality of life are available. These include symptom-specific 
questionnaires, such as the ones developed by Vaizey et al. [1] and Wexner et al. [2] 
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and the faecal incontinence quality of life (FIQOL) scale developed by Rockwood 
et al. [3], and also generic questionnaires such as the Short Form 36 (SF 36) [4].
A full examination of the patient, including the abdomen and perineum and 
a neurological examination in some cases, is necessary. Beneficial investigations 
include a flexible sigmoidoscopy, anal manometry (resting and squeeze pressure), 
rectal compliance, pudendal nerve terminal motor latency (PNTML) and endoanal 
ultrasound (EAUS). Clinicians, however, need to be able to determine which test to 
perform, and when, as well as be able to correctly interpret the results.
The management of FI is complex and multidisciplinary, involving the general 
practitioner, continence nurse, physiotherapist, gastroenterologist, urologist and 
colorectal surgeon. Conservative measures, which include patient education and 
support, improvement in diet and bowel habit, judicious use of anti-diarrhoeal 
medication and pelvic floor exercises, are used in the first instance. This is, in 
fact, recommended in the UK by the National Institute for Clinical Excellence 
(NICE) guideline ‘CG49 Faecal Incontinence’ [5]. If these measures fail, surgical 
intervention may be necessary. A variety of surgical options are available, with the 
appropriate therapy being selected depending on the cause of the incontinence and 
the patient’s cognitive function and general physical condition (Table 1). One of the 
surgical options available is the use of anal bulking agents.
1. Restoration and improvement of residual sphincter function
a. Correcting a defective external anal sphincter
Sphincteroplasty (end-to-end repair; overlap repair)
b. Correcting a defective pelvic floor:
Levatorplasty
Postanal repair
Total pelvic floor repair
c. Correction of anorectal deformities
d. Sacral nerve stimulation (SNS)
e. Posterior tibial nerve stimulation (PTNS)
2. Increasing the outlet resistance of the anal sphincter
a. Augmentation of the anal sphincter and anal cushions (anal bulking agents)
b. Anal submucosal fibrosis (SECCA)
c. Anal encirclement (Thiersch procedure)
d. Non-dynamic graciloplasty
3. Dynamic sphincter replacement
a. Dynamic graciloplasty
b. Artificial anal sphincter
4. Antegrade continence enema (ACE)
5. Faecal diversion
a. Colostomy
b. Ileostomy
Table 1. 
Surgical options in the management of faecal incontinence.
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2. Anal bulking agents
Anal bulking agents have emerged as a treatment for FI, following the success 
of bulking agents for urinary stress incontinence in females. In the urology setting, 
bulking agents have been employed to augment the bladder neck and increase 
urethral resistance [6]. Therefore, the aim of anal bulking agents is to prevent FI by 
closing the anal canal or increasing the pressure within the anal sphincter.
The ideal characteristics of a bulking agent have been described in the literature 
[7]. The injected or implanted substance should be biocompatible, non-migratory, 
non-allergenic and noncarcinogenic. The substance should also be easy to inject or 
implant and should produce an improvement in continence, both in the short term 
and in the long term.
2.1 The evidence for anal bulking agents
Anal injectables and implantables have been used to manage faecal incontinence 
for over 20 years. It may be useful to chart their development over the years and to 
classify this development into three phases. The first phase consists of the initial 
experimental studies that took place in the 1990s. The second phase, from about 
the year 2000 onwards, encompasses an increase in the number of studies using a 
wide variety of agents and injection techniques. The third phase features the latest 
generation of anal bulking agents, the implantable polyacrylonitrile, available as 
Gatekeeper (GK) and Sphinkeeper (SK) devices.
2.2 Initial studies: The first phase
Anal bulking agents were first described in 1993 by Shafik [8]. Shafik, an 
Egyptian surgeon, is considered to be a pioneer in this field. In his first study, he 
described the outcomes following the injection of 5 ml of PTFE (polytef/Teflon) 
paste in 11 patients, 7 of whom had incontinence following a lateral internal sphinc-
terotomy for anal fissure. In another study, the same author used 60 ml of abdomi-
nal wall fat as a submucosal injection into the rectal neck at 3 and 9 o’clock in 14 
patients with partial faecal incontinence [9]. Pescatori’s group from Rome, Italy, 
reported the use of anal injection of autologous buttock fat to restore continence 
in one patient who had poor results following a sphincteroplasty. This patient’s 
continence improved following repeated injections [10].
The indications for injection of the anal bulking agents in these studies were 
various. Most patients had passive FI, but some had urge incontinence, indicating 
EAS disruption. The results of these initial studies showed that continence was 
improved in the short term. However, the medium- and long-term results were 
poor, probably because of the resorption or migration of the injected material. 
Reinjection was necessary in order to maintain continence.
A number of safety issues were raised with these studies. Teflon could poten-
tially cause granuloma formation and sarcomas. The injection of autologous fat as a 
bulking agent in urology has been implicated in fatal fat embolism and stroke.
2.3 The second phase
The second phase in the development of anal bulking agents consisted of a wide 
variation in the types of materials used, surgical technique and clinical indications 
[11]. Some of the materials used to bulk the anal sphincter were being used in urol-
ogy to augment the bladder neck. Nine different types of injectable bulking agents 
have been used in these studies (Table 2).
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Type of bulking 
agent
Commercial 
name(s)
Injection site Injection route Published 
studies
No. of 
patients
Silicone biomaterial. 
Polydimethylsiloxane 
elastomer particles 
suspended in a 
biocompatible 
hydrogel made of poly-
N-vinyl-pyrrolidone
PTQ; 
Bioplastique
Intersphincteric; 
within IAS
Transsphincteric 21 619
Carbon-coated 
zirconium beads, 
comprised of pyrolytic 
carbon-coated beads 
suspended in a 
water-based carrier gel 
containing β-glucan
Durasphere Submucosal Transmucosal; 
transsphincteric
7 187
Spherical particles 
of calcium 
hydroxylapatite, 
suspended in a gel
Coaptite Submucosal Transsphincteric 1 10
Dextranomer 
microspheres and 
stabilised sodium 
hyaluronate in 
phosphate-buffered 
0.9% sodium chloride 
solution
NASHA 
Dx, Zuidex, 
Solesta
Submucosal Transmucosal 5 192
Glutaraldehyde cross-
linked collagen
Contigen Submucosal Transmucosal 2 90
Synthetic non-
particulate hydrogel 
consisting of water 
(97.5%) and cross-
linked polyacrylamide 
(2.5%)
Bulkamid Intersphincteric Intersphincteric 1 5
Cross-linked porcine 
dermal collagen 
matrix
Permacol Submucosal; 
intersphincteric
Transmucosal; 
intersphincteric
5 172
8% ethylene vinyl 
alcohol copolymer 
dissolved in dimethyl 
sulfoxide. A spongy 
solid mass forms from 
the solidification 
of the hydrophobic 
copolymer when the 
solvent diffuses away 
on contact with tissue 
fluid
Onyx34 Intersphincteric Intersphincteric 1 21
Expandable silicone 
microballoons filled 
with a biocompatible 
hydrogel made of poly-
N-vinyl-pyrrolidone
Submucosal Transmucosal 1 6
Table 2. 
Injectable materials used in the second phase of studies.
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2.3.1 Indications
The clinical indications for which these bulking agents were used varied from 
study to study. These were:
• Failure of conservative management of faecal incontinence.
• Structurally intact but weak internal anal sphincter. This would be due to 
either primary idiopathic degeneration of the IAS or degeneration secondary 
to tissue disorders such as scleroderma.
• IAS damage (childbirth, haemorrhoidectomy, anal stretch, sphincterotomy) 
(Figure 1).
• Defect in the external anal sphincter.
The main indication was IAS dysfunction or disruption. Unlike the EAS, the IAS 
is not amenable to surgical repair.
2.3.2 Surgical procedure and technique
The bulking agents may be inserted under local, regional (anal or pudendal 
nerve block) or general anaesthesia. The type of anaesthesia used depends on the 
preference of the patient and the surgeon. The patient may be positioned in the 
prone (jackknife), lithotomy or left lateral positions, although the latter position 
may not give a satisfactory view of the anorectum to enable accurate injection. A 
phosphate enema is usually administered preoperatively. The procedure is usu-
ally covered by prophylactic antibiotics, such as intravenous (IV) co-amoxiclav 
1.2 g, cefuroxime 750 mg and metronidazole 500 mg or gentamicin 1.5 mg/kg and 
metronidazole 500 mg at induction.
Figure 1. 
Endoanal ultrasound scan showing a defect in the IAS of a 57-year-old lady with passive faecal incontinence 
following haemorrhoidectomy. The defect is present between the arrows from the 3 to the 5 o’clock positions.
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The injection of the bulking agent varies depending on the type of substance 
used and the clinical indications. Three different routes of needle insertion were 
mentioned in the literature: transmucosal, transsphincteric or intersphincteric. The 
bulking agent was placed submucosally, within the intersphincteric space or within 
the IAS itself. For example, porcine dermal collagen (Permacol) may be injected 
via the transmucosal or transsphincteric route using a disposable 19G needle [12] 
(Figure 2). In patients with an intact IAS, 2.5 ml of Permacol is equally injected 
into the submucosal space at the 3, 7 and 11 o’clock positions above the dentate 
line. In cases of an IAS defect, 5 ml of Permacol may be injected at the site of the 
defect, with 2.5 ml of the substance injected diametrically opposite. With silicone 
biomaterial (PTQ or Bioplastique), four doses of 2.5 ml of silicone are used, using 
an 18G needle [13, 14]. Patients with an intact IAS have the silicone injected trans-
sphincterically into the intersphincteric space at the 2, 4, 8 and 10 o’clock positions. 
In patients with an IAS defect, for example, after a lateral internal sphincterotomy, 
a total of three doses of 2.5 ml of silicone are injected into the defect. A fourth dose 
is injected into the intersphincteric space contralateral to the IAS defect, to provide 
symmetry. With carbon-coated beads (Durasphere), a total of 10 ml is injected in 
four divided doses in the submucosal plane using an 18G needle [14].
It is of utmost importance to ensure that the anal mucosa is not breached during 
injection, since that would allow intra-anal leakage of the substance. Intravascular 
injection must also be avoided.
Once the injection is completed, it is a good practice to leave the needle and 
syringe in place for a few seconds. As the needle is being withdrawn, pressure on the 
needle track by the index finger may prevent leakage of the bulking agent [12].
The bulking agent may be injected freehand, with an anal retractor such as 
Eisenhammer used to identify the IAS and intersphincteric groove. A finger placed 
within the anal canal may be useful to guide the needle to its correct position. 
However endoanal ultrasound has been recommended to guide the needle to an 
optimum position [13], especially if the agent is to be injected into the intersphinc-
teric space or adjacent to a defect in the IAS.
2.3.3 Results
The majority of studies in this second phase of development were mainly case 
series and observational studies. Most of these studies reported either an improve-
ment in the faecal continence scores or less frequent episodes of incontinence over 
time. Anorectal manometry testing is featured in some studies, with some showing 
an improvement in resting or squeeze pressures. Others studies showed no such 
improvement. Clinical improvement was not always associated with an increase in 
Figure 2. 
Porcine dermal collagen (Permacol) in a 2.5 ml syringe.
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these pressures. Quality of life was formally assessed in some of these studies. The 
majority reported an improvement across various domains such as physical and 
social function.
To date there have been 6 randomised trials using anal bulking agents, with 
more than 400 patients. Two trials compared a bulking agent with a sham or saline 
injection. Siproudhis et al. in 2007 [15] compared a silicone biomaterial (PTQ ) 
with a normal saline injection (control) into the intersphincteric space. PTQ did 
not demonstrate any appreciable clinical benefit when compared to the control. 
The trial was however deemed to be too small to detect any differences in conti-
nence. Graf et al. in 2011 [16] compared the injection of dextranomer (NASHA 
Dx) against sham injection (no substance injected). Continence was better in 
the short term (6 months) in the active intervention group, although interest-
ingly about 30% of patients in the control group had an improvement in their 
continence. This same group, the NASHA Dx study group, published the results 
of a prospective multicentre trial in 2014, showing that ‘submucosal injection 
of NASHA Dx provided a significant improvement of FI symptoms in a major-
ity of patients and this effect was stable during the course of the follow-up and 
 maintained for 3 years’.
A small study with 10 patients by Maeda et al. in 2008 [17] revealed significant 
improvement at 6 weeks postinjection using injection of Bulkamid and Permacol. 
Continence decreased slightly in the Permacol group at 6 months. However there 
was no reported difference between the two agents. The numbers were too small 
to detect a difference. Tjandra et al. in 2009 reported the results of a randomised 
study comparing PTQ with carbon-coated beads (Durasphere) [14]. PTQ injection 
was associated with better continence scores and quality of life and was safer than 
Durasphere.
Tjandra et al. in 2004 reported the short-term benefits from ultrasound-guided 
injection of silicone biomaterial (PTQ ) compared with digital guidance [13].
The follow-up for the majority of patients in studies was less than a median of 
3 years. A question on the term durability and effectiveness of these agents is there-
fore raised. The majority (97%) of patients were only followed up once or twice. 
No long-term evidence on outcomes was available, and further conclusions were 
not warranted from the available data. None of the studies reported patient evalu-
ation of outcomes, and thus it is difficult to gauge whether the improvement in the 
continence scores matched the practical symptom and quality of life improvements 
that mattered to the patients.
The majority of patients did not report any complications. The complications 
described were mainly pain, anal bruising and leakage of injected material [11, 12]. 
Less common complications were anal ulceration and infection (local cellulitis and 
abscess formation). There were two reported cases of local giant cell foreign body 
reaction after injection of silicone (PTQ ) [18]. Durasphere has been associated with 
skin rashes and arthritis. Skin patch testing is therefore recommended before using 
this agent [14].
2.4 The third phase: The implantable gatekeeper and Sphinkeeper
A relatively new and innovative development in anal bulking technology is 
the Gatekeeper and Sphinkeeper (THD S.p.A., Correggio, Italy). The material 
used is polyacrylonitrile (Hyexpan). Polyacrylonitrile is an inert, non-allergenic, 
nondegradable material that is also non-immunogenic and noncarcinogenic. First 
developed by Medtronic in Minneapolis, USA, it was originally used as an implant 
in the oesophagogastric junction for the management of gastro-oesophageal reflux 
disease.
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The main indications for the use of the GK and SK are passive faecal inconti-
nence, secondary to IAS dysfunction or damage, where conservative measures or 
injection of other bulking agents such as PTQ or Permacol has failed. However, the 
use of GK and SK in patients with other causes of FI is being explored.
The following are contraindications to the use of the GK and SK. Similar con-
traindications have also been described by the product manufacturers of other anal 
bulking agents:
• Perianal sepsis
• Inflammatory bowel diseases with anorectal involvement (Crohn’s disease, 
ulcerative colitis)
• Anal, rectal or colon cancer undergoing active treatment
• Rectal bleeding of unknown or undiagnosed origin
• Rectal prolapse
• Uncontrolled blood coagulation disorders
• Pelvic radiotherapy
• Immunosuppression
• Pregnancy or planned pregnancy in the next 12 months.
2.4.1 Surgical apparatus, procedure and technique
Whereas the anal bulking agents that were developed in phases 1 and 2 are 
injected into or around the anal canal by means of a hypodermic syringe, the 
Hyexpan prostheses are implanted into the intersphincteric space using a custom-
made gun (Figure 3).
The difference between GK and SK lies in the size of the prostheses. The 
dehydrated GK prostheses consist of thin solid cylinders, 22 mm long and 2 mm 
in diameter. The success of this material depends on its hydrophilic properties. 
Figure 3. 
The gatekeeper gun, made of the dispenser that houses one prosthesis and the delivery system. The Sphinkeeper 
delivery system and dispenser are similar but slightly larger.
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Within 48 hours after implantation in the human tissue, the Hyexpan cylinders 
absorb water to become thicker and shorter. The in vitro maximum diameter is 
6.5 mm and the length is 17 mm (Figure 4). The volume of each individual implant 
increases from approximately 70 mm3 to 500 mm3, a 750% increase. The implant 
also becomes much softer in consistency. On the other hand, the SK prostheses in 
the dehydrated state are thin, solid cylinders, 29 mm long with a diameter of 3 mm, 
changing their size to a length of 23 mm and a diameter of 7 mm within 48 h of 
contact with fluids.
The technique of implantation of the GK and SK is identical. The operation is 
performed under regional or general anaesthesia. Intravenous antibiotics are given 
at induction. The author’s patients receive gentamicin 1.5 mg/kg and metronidazole 
500 mg IV. The patient is placed in the lithotomy position. A strict sterile technique 
is used. The IAS and intersphincteric groove are identified by the placement of an 
anal retractor (e.g. Eisenhammer). The author’s preference is a THD surgy Mini-
light proctoscope, a self-illuminating anal and rectal retractor that gives a very good 
view of the anorectum without causing trauma to the anal sphincter (Figure 5). A 
2 mm incision is made in the perianal skin, 2 cm from the anal verge (Figure 6).
Having attached the dispenser to the delivery system, the needle is inserted 
through the incision and tunnelled to the intersphincteric margin and introduced 
into the intersphincteric space. The needle is then positioned so that the tip would 
lie just beyond the dentate line. When the needle is identified in the correct posi-
tion, by direct vision and palpation and/or by endoanal ultrasound, the prosthesis is 
released into the intersphincteric space (Figure 7).
The steps may be repeated to insert up to 10 prostheses, equidistant from each 
other. The GK has been originally described with the insertion of between 4 and 
6 prostheses, whereas the SK has been described with the use of 10 prostheses. 
The choice of inserting 4 as opposed to 6 or 10 prostheses is arbitrary. The use of 
10 prostheses enables the formation of a circumferential or quasi-circumferential 
intersphincteric ring, akin to an artificial anal sphincter. The prostheses self-fix in 
the desired position, thereby preventing displacement and migration in the major-
ity of cases.
The wounds are closed with a single absorbable suture (Figure 8). At the end of 
procedure, EAUS imaging will show the location of all prostheses. The procedure 
takes about 30 to 40 minutes to complete and is done as a day case. Oral metronida-
zole 400 mg tds is prescribed for 5 days postoperatively. Oral laxatives such as lactu-
lose are prescribed to minimise the risk of constipation. The patients are advised 
to avoid any anal trauma as well as anal intercourse for at least 72 h after implant 
insertion. The patients are followed up after 6 weeks and 3 months thereafter. The 
material remains identifiable both by palpation and by endoanal ultrasonography in 
the postoperative period (Figures 9 and 10).
Figure 4. 
(a) Shape of Hyexpan gatekeeper cylinder at insertion. (b) Fully expanded Hyexpan gatekeeper cylinder 
following contact with water.
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Figure 6. 
Making an incision, 2 cm away from the anal verge, at the 6 o’clock position.
Figure 5. 
Palpating the IAS and the intersphincteric groove at the 6 o’clock position with a THD surgy mini-light 
proctoscope in position.
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Figure 7. 
The gatekeeper needle at the 9 o’clock position, with the endoanal ultrasound probe in place to determine 
correct placement.
Figure 8. 
Up to 10 equidistant circumferential perianal wounds, each closed with an absorbable suture (Monocryl 3/0).
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2.4.2 Results
The first reported experience with the Gatekeeper was by Ratto et al. in 2011 
[19]. This was a study with 14 patients. Eight had idiopathic FI, four had an IAS 
defect, and two had combined IAS and EAS defects. The median follow-up was of 
12 months (ranging from 5 to 48 months). The authors reported a clinically signifi-
cant improvement in continence in 13 patients, a sustained significant improvement 
in the Wexner and Vaizey scores and in the SF36 and FIQOL scores. No complica-
tions have been reported.
The second study was a comparative retrospective study by Parello et al. in 
2012 [20]. Seven patients who had the Gatekeeper implanted were compared to six 
patients who underwent sacral nerve stimulation. The median follow-up was of 
18 months in the Gatekeeper group and 20 months in the SNS group. The authors 
reported a sustained improvement in the Wexner continence scores with both 
modalities of treatment.
Fabiani et al. [21] used Gatekeeper for a group of patients affected by minor 
faecal incontinence. Four out of seven patients complained of passive incontinence 
prior to the procedure. After an average follow-up of 6 months, 6 patients reported 
a Wexner incontinence score under the value of 4, meaning that they rarely experi-
enced symptoms (0 = perfect incontinence and 20 = complete incontinence). Only 
one patient who suffered mixed incontinence failed to respond.
Biondo et al. [22] concluded that Gatekeeper is a safe and effective procedure 
in more than 50% of patients for at least a year after implantation. They found 
that no patients had postoperative or long-term complications. Forty-eight per 
cent of patients were classed as responders, and significant differences were found 
between baseline mean Vaizey scores at 6 months, 12 months and last follow-up. At 
long-term follow-up (2.7 years), those patients that responded were found to have 
maintained an improvement more than 50% of their baseline Vaizey score.
Figure 9. 
Endoanal ultrasound scan (Aloka) at 6 weeks following the implantation of six gatekeeper prostheses in a 
72-year-old male with idiopathic passive faecal incontinence.
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In a multicentre study involving 54 patients and a clinical follow-up for a year, 
Ratto et al. [23] noted that after Gatekeeper implantation, incontinence to gas, 
liquid and solid stool improved significantly, soiling was reduced and the ability 
to defer defaecation was enhanced. All faecal incontinence severity scores were 
significantly reduced, and patients’ quality of life improved. At 12 months, 30 
patients (56 per cent) showed at least 75 per cent improvement in all faecal incon-
tinence parameters, and 7 (13 per cent) became fully continent. Dislodgement 
of a few prostheses was reported, but this made no difference to postoperative 
continence.
The author has carried out more than 40 GK procedures in a single centre 
since 2012. The main indications were idiopathic FI and passive incontinence 
following surgery (anal stretch for anal fissure and haemorrhoidectomy). All 
patients had failed conservative management. There was a significant sustained 
improvement in the median Vaizey scores. The median (range) Vaizey scores 
improved from 16 (12–17) preoperatively to 5 (3–9), 4 (3–7), 4 (3–5), 4 (3–5), 
5 (3–6) and 5 (3–6) at 6 weeks and at 3, 6, 12, 24 and 36 months, respectively 
(p < 0.01, Wilcoxon test). There was also an improvement in the Rockwood qual-
ity of life scores. The author reports no complications apart from minor pain that 
is managed by paracetamol.
Publications on the Sphinkeeper are limited. Ratto et al. [24] treated 10 patients 
with SK and followed them up for 3 months. The study demonstrated that the SK, 
with its larger prostheses than that of GK, is safe and effective. The Pelvic Floor 
Society of the Association of Coloproctology of Great Britain and Ireland is cur-
rently collecting prospective data on the SK from multiple centres in the UK.
Figure 10. 
Endoanal ultrasound scan (B&K) at 6 weeks following the implantation of 10 Sphinkeeper prostheses in a 
68-year-old female with passive faecal incontinence and previous episiotomy.
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3. Discussion
The development of anal injectable and implantable technology over the past 
20 years has taken great strides forwards. Starting with the pioneering efforts of 
Shafik with autologous fat, more materials have been tried and used, the most 
popular being collagen (Permacol) and silicone (PTQ or Bioplastique). These agents 
were associated with variable and inconsistent results. Injections were frequently 
repeated to maintain continence in the long term. The latest generation of anal 
bulking agents is the implantable Hyexpan (Gatekeeper and Sphinkeeper). This 
material fits the criteria for the ‘ideal’ bulking agent. It overcomes most limitations 
of other bulking agents, and its use has shown very promising results.
The choice to implant the GK and SK prostheses into the intersphincteric 
space of the anal canal plays a key role. This location potentially avoids extrusion 
or migration of prostheses (different to what could happen if implanted into the 
submucosa). Moreover, thanks to the rapid increase of their volume, the prostheses 
self-fix and are unlikely to move after deployment.
The mechanism of action of anal bulking agents is a subject of debate. Most 
of the resting anal pressure is the function of the IAS, with some contribution from 
the EAS and anal cushions. Studies of faecal incontinence in patients who have 
undergone a traditional Milligan-Morgan haemorrhoidectomy lend support to the 
concept that anal cushions play an important part in the maintenance of the normal 
mechanism of continence. It is thought that the mechanism of action of a bulking 
agent injected into the submucosal space is an increase in the size of the natural anal 
cushions. On the other hand, a bulking agent injected or implanted into the inter-
sphincteric space would bulk up the size of the anal sphincter. The end result would 
be an improvement in the seal of the lumen of the anal canal at rest and potentially 
an increase in resting anal pressure and in the length of the anal high pressure zone. 
When the injection is placed adjacent to an identifiable IAS defect, a better degree 
of anal canal sealing may be obtained through improvement in the configuration 
and symmetry of the anal canal [7]. Ratto argues that GK and SK, being embed-
ded within the intersphincteric space, thereby pushing the EAS outwards and the 
IAS inwards, ‘may improve sphincter contractility by increasing sarcomere length 
as well as increase the length of the anal canal and provide a powerful “bulking 
effect”’ [24].
It is acknowledged that more research is required in this field. Most studies are 
case series with very few randomised trials. The Gatekeeper and Sphinkeeper, the 
latest generation of anal bulking agents, show promising results. Whether these 
results are maintained in the longer term or not awaits to be seen. The key factor 
however remains that correct patient selection is extremely important to achieve 
good results.
Larger series with longer follow-up and randomised controlled trials are there-
fore necessary. Further development on existing and emerging technology is also 
warranted.
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